Peer-influenced content. Sources you trust. No registration required. This is HCN.
The New England Journal of Medicine
In a recent study, 91% of patients with transfusion-dependent β-thalassemia achieved independence from transfusions following treatment with Exagamglogene Autotemcel.
Hematology May 13th 2024
DocWire News
Exa-cel’s success in the CLIMB THAL-111 trial represents a transformative approach to treating β-thalassemia, eliminating dependency on transfusions and underscoring the potential of gene editing in hematological disorders.
Hematology March 4th 2024
In light of recent findings, medical professionals should consider that while liberal transfusion strategies in myocardial infarction patients with anemia do not substantially decrease the risk of further myocardial infarction or death, the restrictive approach’s potential harms should not be overlooked.
Cardiology January 11th 2024